Loading
A phase 2 trial of Trastuzumab brengitecan, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting.
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC is a phase 2 interventional study registered as NCT07264816 by Sichuan Baili Pharmaceutical Co., Ltd., with 80 participants planned, started 2026-02-03 and due to reach its primary completion in 2027-12. Interventions recorded: BL-M07D1, Pembrolizumab. Conditions listed: Non-squamous Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trastuzumab brengitecan, HER2-mutant non-small-cell lung cancer, SystImmune / Sichuan Biokin, Small-cell lung cancer.
Shares Trastuzumab brengitecan, HER2-mutant non-small-cell lung cancer, SystImmune / Sichuan Biokin, Small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares SystImmune / Sichuan Biokin, Pembrolizumab, Immune checkpoint inhibitors.
Shares Trastuzumab brengitecan, SystImmune / Sichuan Biokin.
Shares SystImmune / Sichuan Biokin, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares SystImmune / Sichuan Biokin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares HER2-mutant non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/